瘦体质与内脏脂肪质量比和胰岛素抵抗之间的预期相关性:NHANES 2011-2018年
Ya Shao1, Longti Li2, Huiqin Zhong3
1Department of Health Management Center, TaiHe Hospital, Hubei University of Medicine, Shiyan, China.
Frontiers in endocrinology
|September 29, 2023
概括
保持健康的瘦体质与内脏脂肪的比率是减少胰岛素抵抗 (IR) 的关键. 这项研究强调了这种平衡对代谢健康的重要性.
科学领域:
- 代谢健康 代谢健康
- 身体组成分析 身体成分分析
- 胰岛素耐药性研究研究
背景情况:
- 身体组成和胰岛素抵抗 (IR) 之间的联系仍在争论中.
- 了解这些关系对于代谢健康管理至关重要.
研究的目的:
- 为了研究脂肪组织,瘦体质量和红外线之间的相关性.
- 分析瘦肉体质量与内脏脂肪比率 (Log LM/VFM) 与IR的关联.
主要方法:
- 使用NHANES数据 (2011-2018) 的横截面研究,共有4981名参与者.
- 采用多重线性回归,平滑曲线拟合和值/和效应分析.
- 使用Log LM/VFM作为IR关联的代理变量.
主要成果:
- 瘦体质量和IR之间的负相关性;内脏脂肪质量的正相关性.
- 记录LM/VFM显示了与IR显著的负相关性,无论是持续的还是明确的.
- 在Log LM/VFM和IR之间确定了非线性关系,观察到值和和效应.
结论:
- 均衡的瘦体质与内脏脂肪的比率对降低胰岛素抵抗有好处.
- 这一发现在各种人口和健康子组中保持了强的地位.
更多相关视频
06:13Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
1.1K
06:28A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
Published on: April 28, 2023
866
相关概念视频
Obesity
523
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
523
Bias in Epidemiological Studies
339
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:
339
Hazard Ratio
152
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
152
